Pharmbio
A-7F Samho Bldg, 83 Nonhyeon-Ro, Seocho-Gu, Seoul, Seocho-Gu, 06775, South Korea
Overview
Pharmbio Korea Company Ltd is a pharmaceutical company. The Company develops drugs for urinary tract infections, diuresis & relaxes urinary tract spasm, gallstones, and difficult digestion.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Medical
- Pharmaceutical
Investment portfolio
- Master Meditech
Participated · Series A · Mar 2021
Master Meditech Inc. announced a KRW 8 billion Series A funding round closed on March 29, 2021. The articles report participation from a mix of corporate and investment firms. Named participants include Samho Green Investment, Paratus Investment (and a Paratus‑managed fund, CP Partners LLC), Spring Camp, Huons Co., Pharmbio Co., INNOCENCE Co.Ltd, King Mind Partners, and Foresite‑Cape Bio New Technology Investment Association. The coverage does not disclose valuation, use of proceeds, revenue, or user metrics. No founding year or company location is provided in the articles.
Team
Bong-Kil Nam
CEO